IRX Therapeutics develops immune therapies to treat cancer and related diseases. The company’s therapies are designed to target and restore the immune system in order to improve a patient’s response to next-generation cancer vaccines and novel targeted therapeutics. IRX Therapeutics was founded by John W. Hadden, M.D., a pioneer in the field of Immunopharmacology. The Company’s product platform under development, which is based on over 30 years of research by Dr. Hadden, seeks to restore the immune system of cancer patients, which is suppressed by the onset of the disease.

The immune system is powerful and patient-specific. The aim of IRX’s therapies is to restore an effective cellular immune response by correcting both dendritic cell and T cell defects. IRX believes the best way to develop effective treatments for cancer is to leverage the strength and ability of the immune system to target and fight cancer.

There is evidence that the Company’s lead product candidate, IRX-2, broadly restores the immune system. This primary cell-derived biologic seeks to overcome cancer–induced immune suppression and restore anti-tumor response, vital steps in successfully treating cancer. IRX-2’s multiple therapeutic proteins are believed to work synergistically to activate multiple arms of the immune system.

Phase 2 clinical trials for IRX-2 have shown it is well tolerated by patients and has a good safety profile, which would allow it to be combined with a vast number of cancer treatment regimens.

Therapeutic cancer vaccines and targeted therapies are now showing clinical success and are viewed as the future of cancer treatment. The Company believes that combining these next-generation cancer vaccines with IRX-2 has the potential to improve their effectiveness. As a result, IRX-2 can play an important role in helping a wide range of treatments to potentially extend the lives of patients.